Please sign in to follow a disease.
Scientists hunt for biomarkers to unlock rare eye disease treatments
NCT ID NCT07063719
First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study aims to find biological markers (biomarkers) in blood, tears, and eye cells from 110 adults with seven rare eye diseases. Researchers will compare these markers between patients and healthy controls to see if they differ and if they relate to disease symptoms. The goal is to better understand these diseases and support future drug development.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify key biological markers that help design and test new treatments for rare eye diseases.
- What could go wrong
- This is an observational study, not a treatment trial. It is early-stage research, and the findings may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patient group: * Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study) * Willingness and ability to read and understand the informed consent. * Diagnosis (including genotype, if needed) of REDs. * Affiliation with a social security scheme or beneficiary of such a scheme. RED 1 - AAK Diagnosis criteria * Compatible slit lamp examination (iris/pupillary abnormalities, with or without corneal opacification, vascularization, cataract, glaucoma). with or without: * Foveal hypoplasia and optic disc malformations as detected through fundus examination or OCT tomography * Compatible anterior segment OCT or high-frequency ultrasound biomicroscopy (UBM) * Positive genetic testing RED 2 - NK Diagnosis criteria * Compatible history and slit lamp findings of one of the three stages of the Mackie classification (I - punctate keratopathy; II - persistent epithelial defect; III - stromal involvement) * Reduced/absent corneal sensitivity * Exclusion of infectious or toxic etiologies with or without: * confocal microscopy findings RED 3 - LSCD Diagnosis criteria * Compatible history and slit lamp examination (e.g. corneal conjunctivalization with persistent epithelial defects, loss of limbal anatomy or irregular staining with fluorescein) with or without: * confocal microscopy findings RED 4 - OCP Diagnosis criteria * Compatible slit lamp examination * Exclusion of infectious or toxic etiologies with or without: * conjunctival /oral biopsy with characteristic mucous pemphigoid findings RED 5 - OC GVHD Diagnosis criteria • Compatible history and slit lamp examination consistent with one of 4 grades of ocular GVHD (1 - conjunctival hyperemia, 2 - fibrovascular changes \<25% of palpebral conjunctiva, 3 - fibrovascular changes \>25%, 4 - \>75% or cicatricial entropion) RED 6 - EEC Diagnosis criteria * Compatible slit lamp examination * Compatible systemic findings with or without: * Positive genetic testing RED 7- CNV Diagnosis criteria * Compatible slit lamp examination of corneal stromal neovascularization (1-4 quadrants) * Exclusion of infectious or toxic etiologies with or without: * confocal microscopy findings Control group: * Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study). * Willingness and ability to read and understand the informed consent. * Non-diagnosis of REDs. * Affiliation with a social security scheme of beneficiary of such a scheme. Exclusion Criteria: Patient group: * Pregnancy, breastfeeding (in case any stress was caused to the woman by the biological sampling). * Descemetocele/impending corneal perforation. * Recent (less than 3 months) ocular surgery. * Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology. * Persons subject to a legal protection measure (under guardianship, curatorship or safeguard of justice) Control group: * Pregnancy, breastfeeding. * Active ocular infection. * Descemetocele/impending corneal perforation. * Recent (less than 3 months) ocular surgery. * Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology. * Persons subject to a legal protection measure. (under guardianship, curatorship or safeguard of justice)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aniridia-associated keratopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Universitaire Cochin, APHP
RECRUITINGParis, France
-
Hôpital Universitaire Necker Enfants malades, APHP
NOT_YET_RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light and vitamin B2 eyedrops tested against corneal blood vessel growth
- Can a new eye drop soothe the burning dryness of ocular GVHD?
- One-shot gene editor aims to correct a brain disorder at its source
- Hackathon for the undiagnosed: mayo clinic launches repository to crack rare disease cases
- Eye surface disease study seeks to unlock vision predictors
- Biobank aims to unlock genetic secrets of rare diseases